The Meals and Drug Administration has licensed secnidazole for the therapy of bacterial vaginosis (BV) and trichomoniasis in sufferers extinct 12 years and older.
The antimicrobial agent, marketed as Solosec, used to be first licensed in 2017 as a therapy for BV in grownup females. In 2021, it used to be licensed for the therapy of trichomoniasis in grownup men and females.
Lupin Prescription capsules, which manufactures the drug, launched the expanded acclaim for adolescents in a news release.
The medication is supposed to be taken as a single dose. It is available in a packet that must restful be sprinkled onto applesauce, yogurt, or pudding and consumed with out chewing or crunching.
The therapy chance might perchance presumably also reduction “address gaps in care associated to adherence,” acknowledged Tom Merriam, an executive director with Lupin.
Bacterial vaginosis is a frequent vaginal infection. Trichomoniasis is the most traditional nonviral, curable STI in the US. Sexual partners of sufferers with trichomoniasis might perchance presumably also be handled at the same time.
Vulvovaginal candidiasis is one amongst the that you are going to be ready to imagine facet effects of secnidazole therapy, the drug’s designate notes.
This legend in the origin regarded on MDedge.com, phase of the Medscape Knowledgeable Community.
